Clinical Trials Search Results - National Cancer Institute

Clinical Trials Search Results - National Cancer Institute

CANCER TREATMENT

• Types of Treatment
• Side Effects
• Clinical Trials Information for Patients and Caregivers
  • Find NCI-Supported Clinical Trials
    • How to Join a Cancer Clinical Trial
    • Help With Clinical Trials Search
  • What Are Clinical Trials?
  • Paying for Clinical Trials
  • Patient Safety
  • Deciding to Take Part in a Trial
  • Questions to Ask about Treatment Clinical Trials
  • Selected NCI-Supported Trials
• A to Z List of Cancer Drugs
• Complementary & Alternative Medicine (CAM)
• Questions to Ask about Your Treatment
• Research

51.

Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571

52.

Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CL-PTL-119, NCI-2015-01040, NCT02346747

53.

Standard of Care Therapy with or without Stereotactic Radiosurgery and/or Surgery in Treating Patients with Limited Metastatic Breast Cancer

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR002, NCI-2014-01810, NCT02364557

54.

P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165

55.

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668

56.

Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722

57.

Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266

58.

Whole-Brain Radiation Therapy with or without Hippocampal Avoidance in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-CC003, NCI-2015-01548, NCT02635009

59.

Fentanyl Sublingual Spray in Treating Exercise-Induced Breakthrough Dyspnea in Patients with Cancer

Status: Active
Phase: Phase III, Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2015-0137, NCI-2015-02132, NCT02597478

60.

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients with Elevated PSA after Initial Treatment

Status: Not yet active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: Not specified
Trial IDs: PROS0076, NCI-2016-00094, 35932, NCT02673151

61.

Study of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: K01DA019446-01, NCI-2016-00379, DPMC, NCT00419731

62.

68Ga-PSMA PET/MRI in Finding Tumors in Patients with Intermediate or High-Risk Prostate Cancer Undergoing Surgery

Status: Active
Phase: Phase III, Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: PROS0075, NCI-2016-00092, 35931, NCT02678351

63.

Online Social Networking in Managing Chronic Disease in Patients with Rheumatoid Arthritis

Status: Active
Phase: Phase III, Phase II
Type: Health services research
Age: 18 and over
Trial IDs: 2015-0349, NCI-2016-00563, NCT02717403

64.

A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: NI-0501-04, NCI-2016-00657, 2012-003632-23, NCT01818492

65.

Selinexor in Advanced Liposarcoma

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 12 and over
Trial IDs: KCP-330-020, NCI-2016-00746, 2015-003594-14, NCT02606461

66.

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400C, NCI-2014-01380, NCT02154490, NCT02785939

67.

A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 2215-CL-0201, NCI-2016-00914, 2015-001790-41, NCT02752035

68.

68Ga-RM2 PET/MRI in Detecting Prostate Cancer in Patients with Biochemical Recurrent and CT Scan Negative Prostate Cancer

Status: Active
Phase: Phase III, Phase II
Type: Genetics
Age: 18 and over
Trial IDs: PROS0074, NCI-2015-01993, 348, NCT02624518

69.

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968

70.

Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327

71.

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride with or without Bevacizumab after Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GOG-0213, NCI-2009-00587, CDR0000546714, NCT00565851

72.

Comparison of Different Types of Surgery in Treating Patients with Stage IA Non-Small Cell Lung Cancer

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 140503, NCI-2009-00447, CDR0000555324, ECOG-40503, NCT00499330

73.

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Status: Temporarily closed
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788

74.

Risk-Directed Therapy in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and under
Trial IDs: TOTXVI, NCI-2011-01254, NCT00549848

75.

Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers

Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CDR0000577892, NCI-2015-01484, NCI-2014-01372, SINGAPORE-07-32-LGI, SINGAPORE-ASCOLT, SINGAPORE-ICR-02, ICR-02, NCT00565708